In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
ID: 345388Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345388

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-074.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability" (FOA Number PAR-23-074). This initiative aims to encourage research applications that focus on detailed phenotyping and hypothesis-driven studies utilizing knockout mouse strains developed by the International Mouse Phenotyping Consortium (IMPC), with the goal of investigating critical genes involved in embryonic development and associated disorders. The funding opportunity is significant for advancing understanding of congenital diseases and infertility, with a maximum budget of $499,999 per year and a project period of up to five years. Interested applicants must adhere to NIH guidelines and submit their proposals by the initial application deadline of June 5, 2023, with further inquiries directed to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-074-Full-Announcement.html
    PAR-23-074.html
    The Department of Health and Human Services, through the National Institutes of Health, has announced a funding opportunity (FOA) titled “In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability" (FOA Number PAR-23-074). This initiative encourages research applications focusing on detailed phenotyping and hypothesis-driven studies utilizing knockout (KO) mouse strains developed by the International Mouse Phenotyping Consortium. The aim is to investigate critical genes involved in embryonic development and associated disorders, facilitating a deeper understanding of congenital diseases and infertility. Key deadlines include an initial application due date of June 5, 2023, with a maximum project period of five years and budgets up to $499,999 per year. The funding targets institutions such as higher education and nonprofit organizations. The FOA emphasizes a rigorous application process, requiring adherence to NIH guidelines and encouraging exploration of both hypothesis-driven and non-hypothesis-driven research approaches. Researchers should utilize existing resources and data from the KOMP2 program, contributing to shared scientific knowledge and addressing pertinent health issues accordingly. The document details eligibility, application procedures, review criteria, and compliance expectations, aiming for a broad range of impactful scientific inquiries.
    Similar Opportunities
    In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for in-depth phenotyping and research using knockout mouse strains that exhibit embryonic or perinatal lethality or subviability, under the R01 Clinical Trial Not Allowed grant mechanism. This initiative aims to encourage applications that leverage the International Mouse Phenotyping Consortium (IMPC) resources to better understand genetic functions related to congenital diseases and structural defects, particularly those affecting embryonic development and fertility. The program is part of a broader effort to catalog mammalian gene function, with an award ceiling of $499,999 per year for projects lasting up to five years. Interested applicants must submit their proposals by January 7, 2026, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Informatics, Coordination and Service Center for the Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Informatics, Coordination and Service Center (ICSC) for the Mutant Mouse Resource and Research Centers (MMRRC) consortium through the funding opportunity RFA-OD-25-012. The ICSC is tasked with providing essential informatics and coordinating services, including the development and maintenance of data management systems, operation of a public website and customer service center, and facilitation of interactions among biomedical researchers. This initiative is particularly focused on integrating New Approach Methodologies (NAMs) with traditional animal research to enhance predictive models of human diseases. The estimated total program funding is $878,000, with a maximum annual budget cap of $650,000 in direct costs, and applications are due by May 2, 2026. For further inquiries, interested applicants can contact Oleg Mirochnitchenko, Ph.D., at ORIPDCM@mail.nih.gov.
    Informatics, Coordination and Service Center for the Mutant Mouse Resource and Research Centers (U42 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the Informatics, Coordination and Service Center (ICSC) within the Mutant Mouse Resource and Research Centers (MMRRC) consortium, aimed at enhancing biomedical research through improved informatics services. The initiative seeks to support projects that develop and assist resources related to animal and biological materials, focusing on the integration of new approach methodologies (NAMs) alongside traditional animal-based research. This funding opportunity, utilizing the U42 activity code, is expected to provide a total of $878,000, with one award anticipated, and applications will be accepted starting in Summer 2025, following the NOFO publication in Spring 2025. For further inquiries, interested applicants can contact Dr. Oleg Mirochnitchenko at oleg.mirochnitchenko@nih.gov or by phone at 301-425-0479.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)." This initiative invites applications aimed at improving the utility of mammalian cancer models, including organoids and tumoroids, to better represent human biology and address translational deficiencies in existing models. The funding seeks to advance cancer research by fostering innovative approaches to validate these models and enhance their clinical relevance, ultimately aiming to improve patient outcomes. Eligible applicants can receive up to $499,000 per year for a maximum of five years, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html.
    Animal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the establishment of Animal and Biological Material Resource Centers under the Notice of Funding Opportunity (NOFO) RFA-OD-25-011. This initiative aims to support the creation, preservation, and distribution of high-quality laboratory animals and biological materials, while also integrating new approach methodologies (NAMs) that complement traditional animal-based research. The program is crucial for enhancing research infrastructure and ensuring the availability of resources that facilitate scientific rigor and reproducibility in biomedical research. A total funding amount of $1.3 million is anticipated to support at least two awards annually from FY 2023-2025, with applications due by January 9, 2029. Interested applicants can reach out to the Office of Research Infrastructure Programs at ORIPDCM@mail.nih.gov for further information.
    Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the development of animal models and related biological materials for research, designated as an R21 Exploratory/Developmental Research Grant. This funding initiative aims to support innovative projects that enhance, characterize, and preserve animal models relevant to human health and diseases, with a focus on studies that encompass multiple body systems or disease categories rather than single-disease research. The total funding available is $200,000, with a project period limited to two years, and applications are due by January 7, 2028. Interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-273.html.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovation Grants to Nurture Initial Translational Efforts (IGNITE)" aimed at developing and validating model systems for neurotherapeutic discovery. This initiative encourages proposals for animal models or ex vivo systems that accurately replicate the characteristics of specific neurological or neuromuscular disorders, with the goal of enhancing the translational relevance of these models to improve drug development processes. The program utilizes a phased award mechanism (R61/R33) and requires collaboration with clinical experts, along with a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research. The total funding available is $750,000 over three years, with a maximum of $499,000 in direct costs per year. Key submission dates begin with the earliest application due date of January 18, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)," aimed at improving the utility of mammalian cancer models in translational research. This initiative seeks projects that enhance the accuracy and application of models, such as organoids and tumoroids, to better represent human biology and inform clinical practices, addressing current limitations and fostering innovation in cancer research methodologies. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with a maximum funding amount of $499,000 per year for projects not exceeding five years. Interested parties should submit their applications through Grants.gov, with deadlines beginning January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This grant seeks to support innovative research that develops novel tools and technologies, enhances understanding of drug mechanisms, and improves therapeutic options for these populations, particularly those with disabilities. The initiative is part of the R21 Exploratory/Developmental Research Grants program, with a funding cap of $275,000 over a potential two-year period, and requires a Data Management and Sharing Plan as part of the application process. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with the application deadline set for May 7, 2026.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (PAR-25-327), aimed at supporting Investigational New Drug (IND)-enabling studies and preparations for First-in-Human (FIH) clinical trials. This initiative focuses on advancing innovative gene-based therapies, such as oligonucleotides and viral vector approaches, for ultra-rare disorders affecting fewer than 6,000 patients, with an emphasis on projects that demonstrate robust proof of concept data and readiness for clinical trials. Eligible applicants include a wide range of organizations, including higher education institutions and various nonprofit and for-profit entities, with applications requiring detailed project planning and compliance with Good Manufacturing Practices (GMP). The application period opens on January 9, 2025, with a close date of October 8, 2027, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.